iptacopan — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2027-01-29 in 4mo
ESTIMATED |
READOUT
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
Phase 3 · C3G |
NVS NOVARTIS AG | iptacopan |
ClinicalTrials.gov ↗
✓ Source-checked 2026-10-01
Sponsor-projected date — can change
|